Articles tagged with Lung Cancer
Researchers identified two previously unreported resistance mechanisms and found that resistance-conferring mutations can disappear after treatment is discontinued. Repeat biopsies provide critical information for guiding treatment decisions.
A large prospective study of black and white smokers found that mentholated cigarettes are associated with a lower lung cancer incidence and fewer lung cancer deaths than regular cigarettes. The researchers also found that menthol smokers reported smoking fewer cigarettes per day, but had similar quit rates as non-menthol smokers.
New research explores the role of microRNAs in understanding immunoregulation, inflammation, and autoimmune diseases. MicroRNAs are also being investigated as therapeutic targets in cancer and potential biomarkers for various diseases.
A new oral drug intended to protect healthy tissue from radiation effects has been found safe for use in advanced non-small cell lung cancer patients. The agent, called manganese superoxide dismutase plasmid liposome, boosted antioxidant levels and reduced inflammation without protecting tumor cells.
Researchers found that MeSeCys killed more lung cancer cells than SeMet, which may explain conflicting results on selenium's health benefits. The study could provide insight into the chemopreventive properties of different selenium forms.
Researchers at the University of Texas M. D. Anderson Cancer Center have identified a new mechanism driving lung cancer metastasis, involving the suppression of microRNA miR-200 by Jagged2. The study found that low levels of miR-200 may indicate susceptibility to Notch inhibitors currently in clinical trial.
Researchers have discovered that T cells from elite HIV controllers upregulate a protein called p21, which inhibits viral replication. This finding may inform the development of new treatments for patients susceptible to HIV's devastating effects. Meanwhile, two new studies shed light on pediatric brain tumors and lung cancer metastasis.
A new treatment strategy using chemotherapy drugs Erlotinib and Gefitinib has been found to be effective in treating a subset of patients with advanced non-small-cell lung cancer. The drugs, which target the EGFR mutation, produced a response rate of over 70% and had fewer side effects compared to traditional treatments.
A recent study published in the Journal of Thoracic Oncology has revealed that pemetrexed, an established chemotherapy drug, can produce significant responses in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer. The treatment was found to be effective in over half of these patients, offering n...
A Australian researcher has been awarded a $4 million fellowship to continue her work on the origin of breast, ovarian and lung cancers. The research aims to understand the basic biology of epithelial organs and identify molecular pathways that go awry in these cancers.
A recent study discovered a blood protein linked to lung adenocarcinoma, which could serve as a diagnostic marker for the disease. Elevated levels of serum amyloid A (SAA) were found in patients with lung cancer, making it a promising target for developing drugs that stop cancer spread.
Researchers suggest that quitting smoking suddenly may be an early symptom of lung cancer. A study found that 48% of patients with lung cancer had quit before diagnosis, most without noticing any symptoms.
Small-screen detected lung cancers with maxSUV of 2.0 or smaller nodules than 10mm have low risk of nodal metastases, suggesting some patients can avoid invasive procedures. This reduces operating time and morbidity associated with lymph node dissection.
Researchers found that high levels of CYP24A1 enzyme can predict lung cancer survival, with patients having higher levels experiencing nearly half the survival rate as those with low levels. The study suggests using vitamin D to prevent or delay cancer recurrence after surgery.
A new phase III trial has shown that erlotinib has comparable efficacy to chemotherapy in non-small cell lung cancer patients whose disease has progressed after first-line treatment. The study found no difference in overall survival or progression-free survival time between the two groups.
Researchers successfully localized single pulmonary nodules in all 19 patients using radio-guided surgery, detecting primary and secondary lung cancers. The technique took an average of 6 minutes to detect the nodule, with no complications during or after surgery.
Researchers discovered that zoledronic acid can prevent lung cancer metastases from recruiting new blood vessels. The drug showed a statistically significant reduction in VEGF and b-FGF levels, suggesting potential anti-angiogenic effects.
Researchers identified AEG-1 as a strong predictor of progression-free survival in patients with EGFR-mutant non-small cell lung cancer treated with erlotinib. Patients with low AEG-1 expression had longer progression-free survival compared to those with high expression.
Researchers predict nearly 1.3 million cancer deaths in Europe in 2011, with a 7% drop in men's death rates and a 6% decrease in women's mortality. The number of lung cancer deaths is increasing steadily, particularly among Polish and UK women, while breast cancer mortality falls.
Cancer rates are expected to nearly double globally by 2030 due to demographic changes and adoption of unhealthy lifestyles. Preventive measures must be widely applied to mitigate the impact.
Research suggests that high levels of circulating DNA, specifically human telomerase reverse transcriptase (hTERT), can indicate a faster progression of lung cancer and lower overall survival. Patients with lower hTERT levels had improved time to progression and higher overall survival rates compared to those with higher levels.
The report finds progress in reducing cancer death rates for lung and prostate cancers among African American men. However, disparities remain, with higher mortality rates from breast, colorectal, and lung cancers in women. The study highlights the critical role of socioeconomic status in cancer disparities.
A study by Elisabetta Rapiti found that women taking tamoxifen had 87% fewer lung cancer deaths than the general population. The research supports a hormonal influence on lung cancer and estrogen's role in patients' prognosis.
Research highlights the importance of symptom management in improving quality of life for patients with stage IIIb or IV lung cancer. A study found that symptom distress was the strongest determinant of quality of life, followed by symptom severity and frequency.
A China Medical University study shows a 10.9-fold increased risk of lung cancer among people with tuberculosis compared to those without the disease. The study followed over 1 million patients and found a mortality rate of 51.1 per 10,000 person-years in the tuberculosis group, nearly six times that of non-tuberculosis patients.
A new UCSF study reveals that older men with high-risk prostate cancer are frequently under-treated, leading to higher mortality rates. The researchers argue that age should not be a barrier to more aggressive treatments that could lead to potential cures.
Patients who develop an acne-like skin rash after starting chemotherapy and cetuximab treatment have better overall survival, progression-free survival, and response rates compared to those without a rash. The study suggests that an early skin rash could be a predictor of treatment success in lung cancer patients.
Researchers at UT Southwestern Medical Center discovered gene expressions in lung tumors and normal tissue that predict patient survival time and guide effective treatments. The study found specific nuclear receptors associated with good prognosis and identified potential drug targets for personalized therapy.
A cluster-randomized clinical trial in Ethiopia found significantly higher nasopharyngeal pneumococcal resistance to macrolides in communities randomized to receive azithromycin compared to untreated control communities. This study highlights the impact of antibiotic selection pressure on developing antibiotic resistance.
Researchers at Boston University School of Medicine have received grants to develop novel tests for early detection of lung cancer in high-risk patients. The grants will focus on identifying subtle differences in cells from the nose or mouth that can detect disease.
Researchers identified six gene markers in early-stage non-small cell lung cancer that can predict tumor relapse and survival rates. The six-gene classifier stratifies patients into low-, intermediate- and high-risk groups with significantly different relapse rates.
Researchers compared treatment outcomes of elderly patients with early-stage lung cancer treated with either surgery or stereotactic radiation therapy. The study found that both treatments had similar long-term survival rates, but surgery had a higher risk of mortality in the first 30 days.
A study found that combining epigenetic therapy and molecular targeted therapy can improve outcomes for patients with elevated E-cadherin levels in advanced lung cancer. The treatment achieved significantly improved overall survival rates compared to erlotinib alone.
Researchers found that adding ipilimumab to paclitaxel/carboplatin improved progression-free survival rates for stage IIIb/IV non-small cell lung cancer patients. The study suggests that ipilimumab may be a valuable addition to standard treatments, potentially leading to better patient outcomes.
The Lancet criticizes Canada and Quebec governments for exporting asbestos, a cause of deadly mesothelioma, to developing countries. The export will continue due to a loan guarantee, sparking protests and concerns about the exploitation of vulnerable populations.
A study found that PET/CT scans can predict local recurrence in lung cancer patients treated with radiofrequency ablation by analyzing lesion size, tumor type, and glucose metabolic activity. This non-invasive tool may help improve diagnosis and treatment of lung cancer.
A study published in The Lancet found that low-dose aspirin reduces mortality from various cancers, including oesophagus, lung, stomach, pancreas, and possibly brain cancer, by 20-30% regardless of dose or smoking status. Benefit is seen with increasing age and may require at least five years of use for significant impact.
Researchers at VCU Massey Cancer Center discovered a previously unknown mechanism in NSCLC cells that contributes to their ability to maintain and grow tumors. The study found that a protein factor regulates the expression of caspase-9, a main player in apoptosis, which could provide a new target for therapies.
Researchers at SomaLogic describe a breakthrough technology that detects biomarkers for lung cancer in its early stages, revealing the presence of a panel of 12 proteins. The SOMAmer technology enables accurate detection and measurement of proteins in just a few drops of blood.
An experimental immunotherapy using a protein called MAGE-A3 is being tested to prevent lung cancer recurrence in patients who have undergone surgical removal of their tumor. The therapy has shown promising results in clinical trials, offering a potential new weapon against non-small cell lung cancer.
Researchers at MIT discovered that restoring the p53 gene function can slow down the spread of malignant lung tumors in mice, but not in benign ones. The study suggests that p53 restoration could help prevent aggressive cancers from metastasizing.
A new study finds that a less invasive method for determining lung cancer stage improves detection of metastases and reduces surgical procedures. The method, which combines endosonography and ultrasound, was more effective than traditional surgical staging in identifying patients who needed further treatment.
A new inhalable dry powder treatment for lung cancer has been shown to significantly increase survival rates, with over 80% of mice surviving for more than 90 days. The treatment method is also less invasive than traditional options, reducing the risk of side effects and improving overall patient outcomes.
A gene-based test accurately identified a subgroup of very high-risk smokers who accounted for over 50% of all lung cancer cases. The study found that targeting these individuals with low-dose CT screening could significantly improve the number of early-stage lung cancer cases found, making screening more cost-effective.
A gene-based test for lung cancer risk assessment motivates smokers to quit or cut down, according to a clinical study. The test, Respiragene, resulted in 32% of smokers quitting altogether and another 48% reducing their cigarette intake.
A study of adolescents found that less than 2% met annual preventive care visit recommendations, highlighting the need for better access to care. Meanwhile, a survey of family physicians revealed that many refer patients elsewhere for vaccines due to inadequate payment and lack of participation in federally-funded programs.
Researchers found distinct DNA alterations in lung tumors from smokers and never-smokers, suggesting two possible disease pathways. The study suggests that lung cancers in never-smokers require further investigation to improve detection and treatment strategies.
Researchers at Hebrew University of Jerusalem discovered that Vav1 plays a wider role in several types of cancer than previously thought. The discovery has implications for targeting this gene in cancer research and identifying potential therapeutic targets.
Researchers found that screening for lung cancer using helical CT scanning reduced lung cancer deaths by 20 percent compared to chest X-rays. The study also showed overall deaths due to any factor were 7 percent lower in those screened with low-dose helical CT.
A national study conducted by the National Cancer Institute found that CT scanning can reduce lung cancer deaths by 20% in former and current heavy smokers. The study, which involved over 53,000 participants, compared low-dose helical CT with standard chest X-ray screening.
Researchers found lung adenocarcinomas in young patients with pediatric cancers, displaying similar gene mutations as adult cases. The tumors may occur prior to chemotherapy treatment and are not always secondary malignancies.
A new study published in the New England Journal of Medicine found that crizotinib caused tumors to stop growing, shrink or disappear in 57-33 percent of patients with a specific genetic mutation. This represents a significant improvement over the current standard treatment, which has a response rate of around 15 percent.
A study published in the New England Journal of Medicine found that over half of patients with a specific type of lung cancer responded well to a new targeted treatment called crizotinib. The medication targets the gene driving the cancer and has been shown to improve patient outcomes, including reduced tumor growth and improved qualit...
Researchers found that maternal KIRs interacting with fetal HLA-C molecules determine trophoblast invasion, affecting recurrent miscarriage and preeclampsia. Meanwhile, a new approach to treating thrombocytopenia involves infusing mature megakaryocytes into mice to generate functional platelets.
Researchers at IRIC discovered a protein complex, EJC, that controls the production of MAPK protein, which acts directly on cells. Targeting this complex could prevent abnormal signal transmission that triggers several cancers.
A biomarker called TCF21 has shown promise in developing a potential screening test for early-stage lung cancer. The biomarker's abnormal expression was found in over 80% of non-small-cell lung cancers, suggesting its potential as a diagnostic tool.
A Phase IIb/III trial shows afatinib benefits patients with lung adenocarcinoma whose cancer progressed after chemotherapy and erlotinib or gefitinib. Patients receiving afatinib experienced delayed disease progression and greater tumor shrinkage, but no significant difference in overall survival.
A Phase II study of the new-generation lung cancer drug PF-299 has shown impressive results in preventing disease progression when administered as a first-line treatment in patients with advanced disease. The study found that 85% of patients with EGFR mutations remained progression-free for at least nine months.
In a phase II study, patients with locally advanced and metastatic NSCLC experienced significant increases in survival time when treated with TTF therapy in combination with chemotherapy. The therapy has also been shown to have clinical efficacy in human trials for other solid tumors, including recurrent glioblastoma.
Erlotinib has been shown to improve progression-free survival in patients with advanced lung cancer carrying EGFR activating mutations. The OPTIMAL trial found that erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination. Safety analyses also showed lower rates of adverse events with erlotinib.